Natera, Inc. (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 1,649 Shares

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 1,649 shares of the firm's stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $156.85, for a total transaction of $258,645.65. Following the completion of the transaction, the insider directly owned 128,556 shares of the company's stock, valued at approximately $20,164,008.60. This trade represents a 1.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, July 21st, Solomon Moshkevich sold 291 shares of Natera stock. The shares were sold at an average price of $139.29, for a total transaction of $40,533.39.
• On Tuesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $166.77, for a total transaction of $500,310.00.
• On Monday, June 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $157.07, for a total value of $471,210.00.
• On Thursday, May 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $150.12, for a total transaction of $450,360.00.
• On Monday, April 28th, Solomon Moshkevich sold 2,206 shares of Natera stock. The shares were sold at an average price of $152.18, for a total transaction of $335,709.08.

Natera Trading Up 2.4%

NTRA stock traded up $3.25 during mid-day trading on Thursday, reaching $141.07. 1,421,449 shares of the stock traded hands, compared to its average volume of 1,212,550. The stock's fifty day moving average is $159.24 and its 200-day moving average is $157.55. The company has a market cap of $19.26 billion, a P/E ratio of -95.97 and a beta of 1.73. Natera, Inc. has a 52-week low of $92.14 and a 52-week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The company had revenue of $501.83 million for the quarter, compared to the consensus estimate of $446.68 million. During the same quarter in the prior year, the company earned ($0.56) EPS. The firm's quarterly revenue was up 36.5% on a year-over-year basis. Equities research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analyst Weigh In

NTRA has been the subject of several recent research reports. Piper Sandler raised their target price on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. Barclays increased their price target on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. UBS Group lifted their price objective on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a report on Friday, May 9th. Finally, Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. One research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $184.63.

Institutional Trading of Natera

Large investors have recently made changes to their positions in the stock. Callan Family Office LLC acquired a new position in shares of Natera during the 2nd quarter worth about $610,000. Vontobel Holding Ltd. increased its position in Natera by 58.3% in the 2nd quarter. Vontobel Holding Ltd. now owns 2,917 shares of the medical research company's stock worth $493,000 after buying an additional 1,074 shares during the period. Maryland State Retirement & Pension System lifted its holdings in shares of Natera by 17.9% during the second quarter. Maryland State Retirement & Pension System now owns 6,311 shares of the medical research company's stock worth $1,066,000 after buying an additional 959 shares during the last quarter. Narwhal Capital Management lifted its holdings in shares of Natera by 33.3% during the second quarter. Narwhal Capital Management now owns 13,325 shares of the medical research company's stock worth $2,251,000 after buying an additional 3,332 shares during the last quarter. Finally, KLP Kapitalforvaltning AS boosted its position in shares of Natera by 1.8% in the second quarter. KLP Kapitalforvaltning AS now owns 44,400 shares of the medical research company's stock valued at $7,501,000 after acquiring an additional 800 shares during the period. Institutional investors own 99.90% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.